We are pleased to announce the signing of two strategic acquisitions: CareFirst Specialty Pharmacy in North America and Injeplast in Brazil. These acquisitions underscore Fagron’s commitment to expanding across our key markets whilst adhering to our disciplined acquisition strategy. Read the complete press release at: https://lnkd.in/eEACvZKM
🚀 Two additional Fagron family members! 🌍 We are proud to share the achievement of two strategic milestones that strengthen Fagron's position as a global leader in pharmaceutical compounding with the acquisitions of CareFirst Specialty Pharmacy in North America and Injeplast in Brazil. 🎉 These acquisitions represent our commitment to expanding our presence in key markets while staying true to our disciplined acquisition strategy. - CareFirst Specialty Pharmacy, based in New Jersey, enhances our footprint in North America’s prevention and lifestyle markets, particularly in the growing segments of hormone replacement therapy and dermatology. - Injeplast, based in São Paulo, brings GMP-certified, high-quality packaging solutions to our Latin American operations and beyond, supporting our Essentials strategy and global reach. These achievements are a testament to the incredible teamwork and dedication of our colleagues, in particular Andrew Pulido, David Young, CPA, MBA, Ricardo da Cruz, Laura Rus and the entire US team and Geraldino Gabriel Neder, Cristiano Oliveira, Aline Silva and the entire Latam team with the support of Philip van Straelen and the M&A team. To everyone involved in making these deals a reality, thank you for your expertise, diligence, and passion for advancing personalizing medicine. Additionally, we are excited to confirm the closing of the EuroOTC acquisition, announced during Q3 2024. We couldn’t be more proud to keep pushing boundaries and delivering exceptional value to pharmacists, patients and prescribers worldwide! 💪🌟 #Fagron #PersonalizingMedicine #PharmaceuticalCompounding #MergersAndAcquisitions #Growth Full read 👇 https://lnkd.in/ekEa9ZVE